INTRODUCTION
============

In general, drug hypersensitivity reactions (DHR) are classified as immediate type reactions when occur in 1 hour after drug intake and are mostly IgE mediated such as urticaria and anaphylaxis. Nonimmediate type hypersensitivity reactions (HRs) including maculopapular eruptions and fixed drug eruptions which are mediated by T cells occur in one or more hours after drug ingestion \[[@B1]\]. Immunologically, the pathogenic mechanism differs and, by producing different types of cytokines, T cells play a major role in all types of HRs either by regulating IgE production or acting as effector cells \[[@B2]\].

Immediate or nonimmediate type HRs due to different drugs in different times can be experienced. According to some authors, an IgE-mediated reaction might be followed by a T-cell-mediated reaction but they concluded that an IgE and T-cell mediated reactions cannot be experienced together \[[@B3]\].

HRs to quinolones which are widely used antimicrobial agents display the same pattern of most drug reactions consisting of immediate and nonimmediate DHRs \[[@B4]\].

Here, we report an unusual case who experienced both immediate and nonimmediate types of HRs due to a test dose of moxifloxacin.

CASE REPORT
===========

A 47-year-old female patient referred to us because of a history of a nonimmediate type HR to radio contrast media that occurred 3 years previously and immediate type HRs to clarithromycin at 2 different times in order to identify safe alternative antibiotics. We started drug allergy work-up with the confirmation of the clarithromycin hypersensitivity which is relatively rare \[[@B5]\]. The prick test performed with clarithromycin was positive \[[@B6]\]. Because claritromycin can lead to false positive result due to irritation effect we offered drug provocation test but the patient refused. Then in order to identify safe alternative antibiotics we performed the skin prick and intradermal tests with moxifloxacin as previously suggested which were negative \[[@B7]\]. Delayed reading of intradermal tests were negative as well. She was then challenged in a single blind placebo controlled manner with moxifloxacin orally. It was planned to give the drug with incremental doses of 5-50-100-100-150 mg with 30 minutes intervals. After the second dose of 50 mg, pruritus and mild erythema on her body occurred in minutes and followed by dizziness. Patient\'s pulse was very weakly palpable, tachycardic and the blood pressure was very low that could not be measured. She was treated immediately with 0.5 mg of epinephrine, fluid replacement, 40 mg of methylprednisolone (intravenous) and 45.5 mg of pheniramine (intravenous). On the following day she returned with macular eruptions on the trunk and on the proximal extremities which had started with pruritus approximately 20 hours after the drug ingestion ([Fig. 1A](#F1){ref-type="fig"}). Her biochemical tests and differential blood counts were normal. She did not consume any other drugs concomitantly and she had no signs or symptoms of infections. She was treated with methylprednisolone and approximately in 10 days eruptions resolved. A patch test performed with moxifloxacin diluted in petrolatum to obtain the drug concentration of 30% was applied on the upper back approximately 2 months later, after the resolution of signs and symptoms, was found positive ([Fig. 1B](#F1){ref-type="fig"}), confirming nonimmediate type HR reaction to moxifloxacin \[[@B7]\]. To check the possible irritation effect of the drug, we performed patch test with the drug in 5 patients who were known to tolerate moxifloxacin and all they were negative. In order to support the diagnosis of immediate and nonimmediate type reactions, lymphocyte transformation test (LTT) and intracellular interleukin (IL)-4 and interferon-gamma (IFN-γ) levels and basophil activation test (BAT) were performed as described in the literature \[[@B8]\]. A stimulation index for LTT was defined as proliferation ratio of moxifloxacin-specific CD4^+^ T cell to unstimulated cells and result of BAT was interpreted as positive when the percentage of CD63 was 5% above the negative control \[[@B8]\]. BAT was negative while the CD4^+^ T-cell proliferation stimulation indexes were found 1.75 and 1.65 in doses of 5- and 10-μg/mL moxifloxacin, respectively. Moreover, intracellular IL-4 level was high and IFN-γ level was low in CD4^+^ T cells when compared with a healthy subject ([Fig. 2](#F2){ref-type="fig"}). She was subsequently able to tolerate clindamycin.

![(A) Macular eruptions developed 20 hours after drug ingestion. (B) Positive patch test performed with moxifloxacin.](apa-8-e26-g001){#F1}

![(A) Proliferation of CD4^+^ T cells in response to moxifloxacin: demonstrates the expansion of CD4^+^ T cells during culture with doses of 5- and 10-μg/mL moxifloxacin. (B) Intracellular interleukin-4 level was higher and interferon-γ level was lower in CD4^+^ T cells than the levels of the healthy subject. Both results proved that the hypersensitivity reaction was mediated by CD4^+^ T cells. SI, stimulation index; US, unstimulated; PHA, phytohaemagglutinin.](apa-8-e26-g002){#F2}

DISCUSSION
==========

This case report describes both an immediate and a nonimmediate type of HR occurring consecutively due to a test dose of quinolone. Although *in vitro* diagnostic tests partially support the diagnosis, the clinical observations confirm the possibility of consequent occurrence of these reactions in only 20 hours.

Nonimmediate HRs to quinolones which are widely used antibiotics, are less frequent than immediate reactions and maculopapular exanthemas and fixed drug eruptions are the more commonly reported nonimmediate HRs to quinolones \[[@B4]\].

To the best of our knowledge, our case is the first one presenting with both immediate and nonimmediate reactions with the test dose of a drug in 20 hours. As methylprednisolone and antihistamine were used without any adverse event for the patient\'s previous drug reactions, they were not implicated for the macular eruptions in the late phase.

The negative BAT and skin test results failed to confirm an IgE-mediated mechanism. BAT can be very useful in supporting diagnosis of drug induced severe immediate type of HRs \[[@B9][@B10]\]. However, it has been previously reported that in quinolone hypersensitivity both skin testing and BAT can be found negative \[[@B5]\].

Additionally, although the stimulation index in LTT was low, intracellular cytokine responses supported the activation of CD4^+^ T cells. Regarding these *in vivo* and *in vitro* test results we can hypothesize 3 explanations: (1) Since we could only show a T-cell mechanism, it could be an accelerated T-cell response with an early starting T-cell mediated reaction which mostly appears as urticaria and has been reported especially with beta lactams \[[@B11]\]. However our case did not fit into this type of reaction especially in the context of her clinical features. (2) It could be both immediate and nonimmeditae type of sensitizations to the same drug although we could not confirm an IgE-mediated sensitization. (3) Lastly, it could be a biphasic T-cell driven HR, starting like an immediate reaction than evolving to a nonimmediate type HR. In 80\'s van Loveren et al. \[[@B12]\] described an early component of delayed type hypersensitivity mediated by T cells and mast cells. They showed that mast cell activation was caused by a T-cell derived antigen binding factor suggesting a biphasic HR mediated both by T cells and T-cell dependent mast cells and this reaction was not elicited in mast cell deficient mice in their animal study \[[@B12]\]. Although biphasic reactions were classically induced by proteins and to date any biphasic reactions were not reported with a drug, this pathogenic mechanism might explain our patient\'s reaction.

In conclusion, this is the first case report which presents a HR starting as anaphylaxis in minutes and progressing into macular eruptions in 20 hours after intake of a single dose of moxifloxacin. Although it is uncommon, clinicians must be aware that drugs can cause such unusual HRs.

**Author Contributions:** Conceptualization: Semra Demir, Nilgun Akdeniz, Esin Aktas-Cetin, Asli Gelincik. Data curation: Semra Demir, Derya Unal, Muge Olgac, Nilgun Akdeniz, Esin Aktas-Cetin. Formal analysis: Semra Demir, Nilgun Akdeniz, Esin Aktas-Cetin, Suna Buyukozturk. Investigation: Semra Demir, Derya Unal, Muge Olgac, Nilgun Akdeniz, Esin Aktas-Cetin. Project administration: Semra Demir, Asli Gelincik, Bahauddin Colakoglu, Suna Buyukozturk. Resources: Semra Demir, Asli Gelincik, Bahauddin Colakoglu, Suna Buyukozturk. Supervision: Asli Gelincik, Bahauddin Colakoglu, Suna Buyukozturk. Validation: Semra Demir, Derya Unal, Muge Olgac, Nilgun Akdeniz, Esin Aktas-Cetin, Asli Gelincik, Bahauddin Colakoglu, Suna Buyukozturk. Writing - original draft: Semra Demir, Derya Unal, Muge Olgac, Nilgun Akdeniz, Esin Aktas-Cetin, Asli Gelincik, Bahauddin Colakoglu, Suna Buyukozturk. Writing - review & editing: Semra Demir, Bahauddin Colakoglu, Suna Buyukozturk.
